Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABL103 |
| Synonyms | |
| Therapy Description |
ABL103 is a bispecific antibody that targets VTCN1 (B7-H4) and TNFRSF9 (4-1BB), which potentially results in activation of T-lymphocytes and enhanced antitumor immune response (Cancer Res (2025) 85 (8_Supplement_1): 5811). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABL103 | ABL-103|ABL 103 | TNFRSF9 Antibody 36 | ABL103 is a bispecific antibody that targets VTCN1 (B7-H4) and TNFRSF9 (4-1BB), which potentially results in activation of T-lymphocytes and enhanced antitumor immune response (Cancer Res (2025) 85 (8_Supplement_1): 5811). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|